<DOC>
	<DOCNO>NCT01843348</DOCNO>
	<brief_summary>This study design evaluate renal function compare Certican base immunosuppressive regimen two different CNIs ( Tacrolimus Cyclosporin A ) versus standard treatment Mycophenolic Acid Tacrolimus de novo renal transplant recipient .</brief_summary>
	<brief_title>12 Month Athena Study : Everolimus vs. Standard Regimen de Novo Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient receive primary secondary kidney transplant Patients willing write informed consent obtain kidney allograft cold ischemia time ( CIT ) &lt; 30 hour negative pregnancy test prior study enrollment Other protocoldefined inclusion/exclusion criterion may apply Other protocoldefined inclusion/exclusion criterion may apply Multiorgan recipient former Graft loss due immunological reason Patients receive kidney nonheart beat donor AB0 incompatible transplant current Panel Reactive Antibody ( PRA ) level &gt; 20 % exist antibody HLAtype receive transplant know hypersensitivity/contraindication immunosuppressant Use investigational drug Patients thrombocytopenia ( platelet &lt; 100,000/mm³ ) , absolute neutrophil count &lt; 2,000/mm³ leucopenia ( leucocytes &lt; 3,000/mm³ ) , hemoglobin &lt; 8 g/dL significant mental illness history malignancy last five year HIV positive uncontrolled hypercholesterolemia hypertriglyceridemia drug alcohol abuse pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>